Riskpilot← Back to searchSign inGet full accessDXCM Sweden AB
ABIn liquidationOrg 5567634836Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20081 employees
Revenue 2021
SEK 0
EBITDA margin
—
-177% vs 2020
Equity ratio
98.8%
Financial strength
Net profit 2021
SEK -2,7M
-422% vs 2020
| Revenue | SEK 0 | — |
| EBITDA | SEK -2,7M | -177% |
| Net profit | SEK -2,7M | -422% |
| Total assets | SEK 10,7M | -30% |
| Equity | SEK 10,6M | -20% |
| Employees | 1 | — |
Legal name
DXCM Sweden AB
Org number
5567634836
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 augusti 2008
Share capital
SEK 0
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Company purpose
Aktiebolagets verksamhet ska vara att utveckla och marknadsföra produkter, utrustning och system vilka syftar till att kontinuerligt mäta blodglukosvärden för personer med diabetes eller annat tillstånd där blodsockervärdet önskas vara känt, samt därtill hörande verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 34 314 | 30 733 | 31 478 | 33 711 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 660 | 1 484 | 2 264 | 3 515 | −2 706 |
| Depreciation & amort. | −13 | −13 | −3 | −0 | −0 |
| EBIT | 1 647 | 1 471 | 2 261 | 3 515 | −2 706 |
| Net financials | −11 | −7 | 2 170 | −1 904 | — |
| Profit before tax | 1 636 | 1 464 | 4 430 | 1 611 | −2 706 |
| Tax | −718 | −590 | −436 | −771 | −0 |
| Net profit | 918 | 874 | 3 994 | 840 | −2 706 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 12 373 | 25 608 | 40 375 | 15 353 | 10 711 |
| Equity | 7 577 | 8 451 | 12 445 | 13 285 | 10 579 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 796 | 17 157 | 27 929 | 2 068 | 132 |
| Total debt | 4 796 | 17 157 | 27 929 | 2 068 | 132 |
EBITDA margin
-270600000.0%
This company
15.8%
Market median
-1712658328% vs market
20172021
Equity ratio
98.8%
This company
38.2%
Market median
+159% vs market
20172021
Return on equity
-25.6%
This company
18.4%
Market median
-239% vs market
20172021
Net profit margin
-270600000.0%
This company
8.1%
Market median
-3340740841% vs market
20172021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172021
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20172021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
US Chief Auditor | Chief Auditor | 2020 – 2021 |
JC Liquidator | Liquidator | 2020 – 2022 |
JM Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2020 – 2022 | |
| Chairman | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of DXCM Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Strauss | Chief Auditor | 0 companies |
| Jenny Christina Margaretha Rundgren | Liquidator | 0 companies |
| Jenny Maria Anita Holmberg | Chief Auditor | 0 companies |
| Patrick Murphy | Board of Directors | 0 companies |
| Erik Hjalmar Björkman | Chairman | 0 companies |
| Grant Fraser | Deputy Board Member | 0 companies |